Literature DB >> 8201324

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

M Rodriguez1, G Lera, J Vaamonde, M R Luquin, J A Obeso.   

Abstract

The motor responses of 14 patients with Parkinson's disease (six previously untreated and eight chronically receiving levodopa) with pronounced asymmetry in the severity of motor signs between the left and right sides of the body were studied. The effects of a short (60 minutes) and a long (16-22 hours) intravenous levodopa infusion as well as of subcutaneous apomorphine (1-6 mg bolus) were assessed. Four different tapping tests were used to measure motor function. For all pharmacological tests, the more affected side showed a shorter response duration, increased latency, and greater response magnitude than the less affected side. These differences were more pronounced in those patients receiving chronic levodopa treatment. As apomorphine is not dependent on dopamine storage capacity, these findings suggest that postsynaptic mechanisms play an important part in the origin of motor fluctuations in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201324      PMCID: PMC1072915          DOI: 10.1136/jnnp.57.5.562

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations.

Authors:  S T Gancher; J G Nutt; W Woodward
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

2.  Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.

Authors:  M H Marion; F Stocchi; N P Quinn; P Jenner; C D Marsden
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

3.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

4.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

5.  [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.

Authors:  C Pimoule; H Schoemaker; G P Reynolds; S Z Langer
Journal:  Eur J Pharmacol       Date:  1985-08-15       Impact factor: 4.432

6.  Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects.

Authors:  R Raisman; R Cash; M Ruberg; F Javoy-Agid; Y Agid
Journal:  Eur J Pharmacol       Date:  1985-07-31       Impact factor: 4.432

7.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

8.  The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

Authors:  K L Leenders; E P Salmon; P Tyrrell; D Perani; D J Brooks; H Sager; T Jones; C D Marsden; R S Frackowiak
Journal:  Arch Neurol       Date:  1990-12

9.  MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans.

Authors:  J S Perlmutter; M R Kilbourn; M E Raichle; M J Welch
Journal:  Neurology       Date:  1987-10       Impact factor: 9.910

10.  Dopamine D2 receptor density remains constant in treated Parkinson's disease.

Authors:  M Guttman; P Seeman; G P Reynolds; P Riederer; K Jellinger; W W Tourtellotte
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

View more
  12 in total

1.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 3.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

4.  Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

Authors:  U K Rinne; F Bracco; C Chouza; E Dupont; O Gershanik; J F Marti Masso; J L Montastruc; C D Marsden
Journal:  Drugs       Date:  1998       Impact factor: 9.546

5.  A simple model to explain the motor fluctuations seen in Parkinson's disease.

Authors:  D E Bateman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

6.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

Authors:  P A Kempster; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

7.  The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Authors:  Fulvio Bracco; Angelo Battaglia; Carlos Chouza; Erik Dupont; Oscar Gershanik; Jose Felix Marti Masso; Jean-Louis Montastruc
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

10.  Asymmetrical effect of levodopa on the neural activity of motor regions in PD.

Authors:  Kristina Martinu; Atsuko Nagano-Saito; Stuart Fogel; Oury Monchi
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.